Inflexion has acquired Rosemont Pharmaceuticals
Inflexion has acquired Rosemont Pharmaceuticals, the UK’s leading liquid pharmaceuticals business. The business was carved out of listed parent company, Perrigo.
Rosemont Pharmaceuticals is the UK’s leading liquid pharmaceuticals business. Its portfolio of oral liquid medicines includes licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.
Rothschild & Co advised on the acquisition of this transaction. For further detail please contact Karen Dawaf.